CD163 and breast carcinoma: While the pan-macrophage marker CD68 has been mostly used to identify TAMs in breast cancer tissues in earlier studies [35], more recent studies have established that a high density of CD163+ TAMs in breast tumors is associated with poor prognosis [36,37,38,39].